

Resource Summary Report

Generated by NIF on Jul 31, 2026

TRA-1-81 (TRA-1-80)

RRID:AB_628386

Type: Antibody

Proper Citation

Santa Cruz Biotechnology Cat# sc-21706, RRID:AB_628386

Antibody Information

URL: http://antibodyregistry.org/AB_628386

Proper Citation: Santa Cruz Biotechnology Cat# sc-21706, RRID:AB_628386

Target Antigen: Human PODXL

Host Organism: mouse

Clonality: monoclonal

Comments: validation status unknown check with seller; recommendations: Flow Cytometry; Immunofluorescence; Immunoprecipitation; Western Blot; Western Blotting, Immunoprecipitation, Immunofluorescence, Flow Cytometry

Antibody Name: TRA-1-81 (TRA-1-80)

Description: This monoclonal targets Human PODXL

Target Organism: rat, mouse, human

Clone ID: TRA-1-80

Antibody ID: AB_628386

Vendor: Santa Cruz Biotechnology

Catalog Number: sc-21706

Record Creation Time: 20250819T224933+0000

Record Last Update: 20250820T032527+0000

Ratings and Alerts

No rating or validation information has been found for TRA-1-81 (TRA-1-80).

No alerts have been found for TRA-1-81 (TRA-1-80).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 70 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Lee N, et al. (2025) Human induced pluripotent stem cell line (PNUSC Ri006-A) derived from a patient with Sanfilippo syndrome type A exhibiting a mutation in SGSH gene. Stem cell research, 84, 103690.

Lee N, et al. (2025) Human induced pluripotent stem cell line (PNUSC Ri005-A) generated from severe type of Hunter syndrome patient carrying exonic deletion (exon 4-7 del) in human iduronate 2-sulfatase gene. Stem cell research, 83, 103639.

Pornratananont G, et al. (2025) Generation of integration-free induced pluripotent stem cell (iPSC) line MURAi002-A from hemoglobin E/?-thalassemia disease patient harboring ?E/?0 (CD41/42, -CTTT) compound heterozygous mutation. Stem cell research, 86, 103743.

Innachai P, et al. (2025) Generation of an integration-free induced pluripotent stem cell line, MURAi006-A, from a hemoglobin E/?-thalassemia patient harboring the ?E/?0 (Codon 17, A > T) compound heterozygous mutation. Stem cell research, 85, 103702.

Yin T, et al. (2025) Generation of two induced pluripotent stem cell lines (FDCHi011-A and FDCHi016-A) from different patients with NBIA5 syndrome carrying WDR45 m.700C > T and m.888G > A mutation. Stem cell research, 89, 103860.

Xue H, et al. (2025) Physiological role and mechanisms of action for a long noncoding haplotype region. Cell reports, 44(6), 115805.

Zhang M, et al. (2025) Generation of an induced pluripotent stem cell line from a Kennedy Disease patient with AR mutation. Stem cell research, 83, 103649.

Zhang X, et al. (2024) Establishment of a non-integrated iPSC (SDQLCHi066-A) line derived from Segawa syndrome patients harboring heterozygous mutations in the TH gene (p.G247S and p.D491H). Stem cell research, 77, 103392.

Ofrim M, et al. (2024) Characterization of two human induced pluripotent stem cell lines derived from Batten disease patient fibroblasts harbouring CLN5 mutations. Stem cell research, 74, 103291.

Shao J, et al. (2024) An achievement has been made in establishing an induced pluripotent stem cell line (SDPHi005-A) from a healthy Chinese male donor. Stem cell research, 77, 103393.

Lim SW, et al. (2024) Generation of green fluorescent protein reporter knock-in iPSC line at the 3'UTR region of the KLOTHO locus. Stem cell research, 80, 103499.

Pornratananont G, et al. (2024) Generation of integration-free human induced pluripotent stem cell line MURAi003-A derived from the peripheral blood mononuclear cells of a donor with homozygous Class I and Class II HLAs (A*11:01, B*46:01; C*01:02; DRB1*09:01; DQB1*03:03). Stem cell research, 80, 103514.

Yin T, et al. (2024) Characterization of a human induced pluripotent stem cell line (FDCHi015-A) derived from PBMCs of a patient harbouring ALDOB mutation. Stem cell research, 78, 103451.

Xin H, et al. (2024) Establishment of a non-integrated iPSC (SDQLCHi068-A) line derived from a patient with autosomal dominant immunodeficiency-14A carrying a heterozygous mutation (c.3061G>A) in PIK3CD gene. Stem cell research, 77, 103385.

Zhang X, et al. (2024) An integration-free iPSC line SDQLCHi065-A from a patient with down syndrome, possessing a 47, XY,+21, inv(9)(p12q21),16qh + karyotype. Stem cell research, 76, 103351.

Ning J, et al. (2024) Establishment of an iPSC line from a NDD patient with a heterozygous mutation in the CTNNB1 gene. Stem cell research, 79, 103487.

Yin T, et al. (2024) Derivation of an induced pluripotent stem cell line (FDCHi014-A) from PBMCs of a seven-year-old patient with a truncating NOVA2 variant (c.625del). Stem cell research, 76, 103369.

Liu N, et al. (2024) Generation of a human induced pluripotent stem cell line (SDQLCHi057-A) from an Isovaleric aciduria patient carrying novel compound heterozygous mutations in the IVD gene. Stem cell research, 76, 103314.

Gao M, et al. (2024) Generation and characterization of an induced pluripotent stem cell (iPSC) line SDQLCHi063-A from peripheral blood mononuclear cells of a patient with Maturity-onset diabetes of the young type 2 carrying GCK exon 1 deletion. Stem cell research, 77, 103389.

Yang X, et al. (2024) Generation and characterization of PBMCs-derived human induced pluripotent stem cell (iPSC) line SDQLCHi050-A from a healthy donor. Stem cell research, 74, 103266.